Keyword: Roche Venture Fund
The series A equips NMD to see whether the efficacy seen in models of myasthenia gravis and amyotrophic lateral sclerosis translates into the clinic.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
Vivet is harnessing the power of gene therapy to target Wilson disease and other rare genetic disorders as it looks to shake off a tough few years for research and sales in the gene therapy field.
Corporate venture capital has long been an important source of capital for early-stage biotechs and shows no signs of diminishing.
Amid ASCO, two upstarts are looking to make their IPO.
Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an executive team made up of Novartis, Sanofi and Gensight veterans, as the company looks to get to work on its gene therapies for a host of rare diseases.
The Nan Fung Group’s venture capital firm Pivotal bioVenture Partners has raised its first fund, totaling $300 million, as it looks to help early-stage life science startups get off the ground. Its founder tells me she aims to not chase investment trends but seek out solid science and management teams.
As Roche continues to try to hit all the bases in this rare disease, its partner PTC Therapeutics has started a midstage study for its candidate against certain forms of spinal muscular atrophy.
Roche Venture Fund and 5AM Ventures have led benchtop sample preparation upstart Purigen Biosystems to an $18.2 million Series A round.
